# CBD and Threat Anticipation in Alcohol Use Disorder: What a Small Randomized Trial Found > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-threat-anticipation-alcohol-use-disorder-rct/ > **Published:** 2026-09-05T17:35:57-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:36-04:00 > **Clinical Summary:** CBD alcohol use disorder randomized trial: In a randomized crossover experiment, 800 mg daily CBD did not measurably change threat-anticipation brain activit... --- CED Clinical Relevance #82 Cannabis Science Evidence Report A double-blind randomized crossover experiment directly tested 800 mg daily CBD against placebo with behavioral and fMRI outcomes, while its small non-treatment-seeking sample sharply limits therapeutic conclusions. Clinical Insight | CED Clinic In a randomized crossover experiment, 800 mg daily CBD did not measurably change threat-anticipation brain activity, cognitive performance, anxiety, or craving in a small non-treatment-seeking alcohol use disorder sample. The study tested a mechanism, not abstinence or treatment efficacy. This small randomized study found no detectable CBD effect on the threat-anticipation outcomes it measured. It does not demonstrate that CBD treats alcohol use disorder, nor does it rule out effects in other tasks, doses, durations, or patient populations. Clinical decisions require patient-specific review. CBDAlcohol Use DisorderRandomized TrialNeuroimagingSafety AudiencePatients, caregivers, clinicians, and cannabis-science readers interested in alcohol use disorder Primary Topicwhether short-course high-dose CBD changes threat-anticipation brain activity, task performance, anxiety, or craving in alcohol use disorder Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42678517/) In a randomized crossover experiment, 800 mg daily CBD did not measurably change threat-anticipation brain activity, cognitive performance, anxiety, or craving in a small non-treatment-seeking alcohol use disorder sample. The study tested a mechanism, not abstinence or treatment efficacy. What This Study Teaches Us After two supervised daily doses, CBD did not differ from placebo on corrected regional or whole-brain fMRI analyses, continuous-performance accuracy or latency, anxiety, or craving during the threat-anticipation task. Sixteen participants contributed behavioral data and fourteen contributed usable imaging data. Why This Matters CBD is often discussed as a possible treatment for alcohol use disorder, but proposed mechanisms and clinical effects remain unsettled. This experiment narrows one question: under these task conditions, short-course high-dose CBD did not produce a detectable threat-anticipation signal. It does not answer whether CBD reduces drinking, relapse, or treatment-seeking symptoms. Study SnapshotStudy TypeRandomized, double-blind, placebo-controlled crossover experimental medicine trialPopulation22 non-treatment-seeking adults with DSM-5 alcohol use disorder were randomized; 16 provided complete behavioral data and 14 provided analyzable fMRI dataInterventionOral CBD 800 mg daily for two days before the reported imaging sessionComparatorMatched placebo, with each participant serving as their own controlWashoutMean 29.2 days between treatment periodsPrimary QuestionWhether CBD altered behavioral, subjective, regional, or whole-brain responses during threat anticipationMain ResultNo significant main CBD effects on corrected regional or whole-brain activation, task performance, anxiety, or cravingAdverse EventsNo serious adverse events; four participants reported events during CBD sessions and four during placebo sessionsPublishedSeptember 1, 2026PMID / DOI42678517 / 10.1007/s00213-026-07148-yMajor LimitationVery small, non-treatment-seeking sample with five imaging datasets excluded for quality Clinical Bottom Line This small randomized study found no detectable CBD effect on the threat-anticipation outcomes it measured. It does not demonstrate that CBD treats alcohol use disorder, nor does it rule out effects in other tasks, doses, durations, or patient populations. The Trial Tested a Mechanism, Not Sobriety The experiment focused on threat anticipation during fMRI after two days of CBD or placebo. It did not test alcohol abstinence, relapse prevention, treatment retention, or long-term drinking outcomes. The Prespecified Treatment Contrasts Were Null CBD did not significantly change corrected regional or whole-brain activation, cognitive task performance, anxiety, or craving. A null result in a small study means no effect was detected under these conditions, not proof that every clinically relevant CBD effect is absent. The Sample Was Small and Selected Only 16 participants contributed complete behavioral data and 14 contributed analyzable imaging data. Participants were not seeking treatment, and clinical heterogeneity, lower severity, or inadequate task engagement may have limited sensitivity. Adverse Events Were Similar Across Conditions No serious adverse events occurred. Four participants reported events in CBD sessions and four in placebo sessions. The brief exposure and small sample cannot establish longer-term safety or uncommon risks at 800 mg daily. Previous-Day Drinking Was a Relevant Covariate Previous-day alcohol use was associated with slower task responses, and craving rose during the scan regardless of treatment. Those observations were not evidence that CBD improved or worsened alcohol outcomes and should not be converted into a treatment claim. How Strong Is This Evidence? Randomization, double blinding, matched placebo, crossover dosing, supervised administration, an extended washout, correction for multiple comparisons, and combined behavioral and neuroimaging measures strengthen the experiment. Where This Paper Deserves Skepticism The analyzable samples were 16 and 14, participants were not seeking treatment, five imaging datasets failed quality review, the task did not clearly increase anxiety, treatment lasted only two days, and the study was not designed to measure drinking reduction or recovery outcomes. What This Paper Does Not Show The study does not show that CBD reduces drinking, prevents relapse, treats alcohol withdrawal, improves treatment retention, or lacks all possible effects in alcohol use disorder. It also does not establish safety for unsupervised 800 mg dosing or longer treatment. How This Fits With the Broader Clinical Conversation Experimental medicine studies can test whether a proposed neural pathway changes before investing in larger clinical trials. A carefully interpreted null mechanism result can be useful because it limits overconfident explanations while leaving different tasks and clinically meaningful outcomes open for study. Dr. Caplan’s Take *I read this as a focused negative experiment, not as a verdict on every CBD question in alcohol use disorder. The treatment did not move the measured threat-anticipation outcomes under these conditions.* *For patients, this paper offers no basis for replacing evidence-based alcohol treatment with CBD. High-dose CBD also requires attention to sedation, liver effects, and drug interactions that this short study could not comprehensively characterize.* What a Careful Reader Should Take Away Short-course 800 mg CBD produced no detectable benefit on the measured threat-anticipation outcomes in a very small randomized crossover sample, and therapeutic effects on drinking were not tested. Evidence Interpretation Guide Table of Contents - [How to Interpret This Whether Short-Course High-Dose Cbd Changes Threat-Anticipation Brain Activity, Task Performance, Anxiety, Or Craving In Alcohol Use Disorder Evidence Without Overstating It](#How_to_Interpret_This_Whether_Short-Course_High-Dose_Cbd_Changes_Threat-Anticipation_Brain_Activity_Task_Performance_Anxiety_Or_Craving_In_Alcohol_Use_Disorder_Evidence_Without_Overstating_It)[A Four-Step Reading Frame](#A_Four-Step_Reading_Frame) - [Eight Clinical Ways to Read This Evidence](#Eight_Clinical_Ways_to_Read_This_Evidence)[This Was Not an Alcohol Treatment Trial](#This_Was_Not_an_Alcohol_Treatment_Trial) - [Name the Null Result Precisely](#Name_the_Null_Result_Precisely) - [Crossover Design Helps, but Sample Size Still Rules](#Crossover_Design_Helps_but_Sample_Size_Still_Rules) - [High Dose Does Not Guarantee a Detectable Signal](#High_Dose_Does_Not_Guarantee_a_Detectable_Signal) - [The Task May Not Have Provoked the Intended State](#The_Task_May_Not_Have_Provoked_the_Intended_State) - [Brief Exposure Cannot Define Long-Term Safety](#Brief_Exposure_Cannot_Define_Long-Term_Safety) - [Recent Drinking Influenced the Experiment](#Recent_Drinking_Influenced_the_Experiment) - [The Next Trial Needs Clinical Outcomes](#The_Next_Trial_Needs_Clinical_Outcomes) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret This Whether Short-Course High-Dose Cbd Changes Threat-Anticipation Brain Activity, Task Performance, Anxiety, Or Craving In Alcohol Use Disorder Evidence Without Overstating It A useful evidence report should let the signal breathe without inflating it. The right question is not whether the paper is positive or negative, but what kind of decision it can responsibly support. ### A Four-Step Reading Frame **Evidence type**Start by identifying whether the paper is a randomized trial, review, meta-analysis, observational study, or protocol. **Population**Ask whether the studied population matches the patient or clinical scenario involving alcohol use disorder. **Outcome meaning**Look at what actually changed, how it was measured, and whether the change would matter in daily life. **Safety and uncertainty**Read limitations and adverse effects as part of the result, not as a footnote. The Research Question What does the current evidence suggest about whether short-course high-dose CBD changes threat-anticipation brain activity, task performance, anxiety, or craving in alcohol use disorder? The Patient Question Does this mean I should use cannabinoids for alcohol use disorder? The Bottom Line The evidence can inform a careful conversation, but it does not replace individualized clinical care. CED Perspective Lens ## Eight Clinical Ways to Read This Evidence Distinct implications for patients, clinicians, methods, safety, and future research Lens OverviewEach viewpoint stays within the verified paper and separates the measured finding from decisions the evidence cannot make. #### This Was Not an Alcohol Treatment Trial Participants had alcohol use disorder, but they were not seeking treatment and the experiment did not measure abstinence, relapse, or reduced drinking. It tested brain, task, anxiety, and craving responses during a laboratory threat-anticipation paradigm after two days of 800 mg CBD. Because the measured contrasts were null, the paper provides no clinical basis for substituting CBD for evidence-based alcohol treatment. The small sample and brief exposure also mean it cannot settle whether different doses, longer treatment, or emotionally salient tasks would produce another result. Lens takeawayDo not translate this mechanism study into a self-directed alcohol treatment plan. #### Name the Null Result Precisely CBD did not differ from placebo on corrected regional or whole-brain activation, continuous-performance accuracy or latency, anxiety, or craving during threat anticipation. That is a focused negative result across several linked outcomes, not a general demonstration that CBD has no neurobehavioral effects. Counseling should distinguish the tested mechanism from therapeutic outcomes. The trial did not measure drinking reduction, withdrawal, relapse, or treatment retention. A clinician can use the paper to temper mechanism-based claims while still recognizing that other CBD questions require different trials. Lens takeawayDescribe what was not detected without expanding the null beyond the tested task. #### Crossover Design Helps, but Sample Size Still Rules Each participant received CBD and placebo in randomized order, with double blinding, supervised dosing, and a long washout. That within-person comparison reduces between-person variability and strengthens interpretation of the immediate treatment contrast. Only 16 participants supplied complete behavioral data and 14 supplied analyzable imaging data. Five imaging datasets were excluded for poor quality. Crossover efficiency cannot fully compensate for limited statistical power, missing data, or the possibility that the task was not sensitive to the intended effect. Lens takeawayValue the randomized crossover design while keeping its very small analyzable sample visible. #### High Dose Does Not Guarantee a Detectable Signal The study used 800 mg of oral CBD daily for two days, with imaging about 90 minutes after the second dose. This is a high pharmaceutical-style dose and a short experimental exposure, not a typical retail CBD pattern. A null result at this regimen does not identify an effective lower or higher dose, establish a dose-response curve, or address chronic treatment. It also does not authorize unsupervised high-dose use, especially when drug interactions, sedation, and medical comorbidity require assessment. Lens takeawayInterpret the tested regimen exactly and avoid assuming that more CBD means more benefit. #### The Task May Not Have Provoked the Intended State The fear-anticipation task activated relevant brain regions, but self-reported anxiety did not significantly increase across the scan. If the task did not generate a strong anxiety response, it may have offered limited room for CBD to reduce that response. This measurement concern does not turn a null result into a positive one. It identifies uncertainty about assay sensitivity. Future experiments need adequately provocative, validated tasks and clinically meaningful endpoints before a proposed stress-modulation pathway can support treatment claims. Lens takeawayA weakly engaged target can limit detection, but it cannot be used to invent efficacy. #### Brief Exposure Cannot Define Long-Term Safety No serious adverse events occurred. Four participants reported events during CBD sessions, including drowsiness, somnolence, lethargy, or fatigue, and four reported events during placebo sessions, with some participants reporting more than one symptom. The sample was too small and exposure too brief to characterize uncommon harms, liver effects, longer-term tolerability, or clinically important drug interactions. People considering high-dose CBD need medication reconciliation and individualized medical review, especially when other sedating or hepatically metabolized drugs are involved. Lens takeawayThe short safety observation is reassuring only within narrow and explicit boundaries. #### Recent Drinking Influenced the Experiment Previous-day alcohol consumption was associated with slower task responses, and craving increased during the scanning session regardless of treatment. These findings show that immediate drinking context can affect behavioral and subjective measurements in alcohol use disorder research. They do not demonstrate that CBD modified those relationships. The previous-day associations were covariate findings, and the craving increase could reflect the task, the broader MRI experience, or both. Clinical interpretation should not turn them into causal alcohol or CBD claims. Lens takeawaySeparate recent alcohol-context observations from the randomized CBD-versus-placebo treatment contrast in this experiment. #### The Next Trial Needs Clinical Outcomes Larger studies should prespecify drinking, relapse, withdrawal, treatment retention, and patient-reported outcomes alongside mechanistic measures. They should also recruit treatment-seeking populations, assess disorder severity, verify exposure, and plan carefully for imaging quality losses. Different tasks may clarify whether CBD acts during direct emotional or alcohol-cue processing rather than anticipation. Until replicated links connect a mechanism to meaningful clinical improvement, neuroimaging findings should remain explanatory hypotheses rather than treatment recommendations in routine addiction care. Lens takeawayMove from small mechanistic signals to adequately powered trials with patient-important outcomes. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=CBD+and+Threat+Anticipation+in+Alcohol+Use+Disorder%3A+What+a+Small+Randomized+Trial+Found&url=https%3A%2F%2Fcedclinic.com%2Fcbd-threat-anticipation-alcohol-use-disorder-rct%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcbd-threat-anticipation-alcohol-use-disorder-rct%2F) [BlueSky](https://bsky.app/intent/compose?text=CBD+and+Threat+Anticipation+in+Alcohol+Use+Disorder%3A+What+a+Small+Randomized+Trial+Found%20https%3A%2F%2Fcedclinic.com%2Fcbd-threat-anticipation-alcohol-use-disorder-rct%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Cannabidiol and neural correlates of threat anticipation in alcohol use disorder.](https://pubmed.ncbi.nlm.nih.gov/42678517/) Related Reading at CED ClinicContinue exploring the evidence[Can You Use Cannabis and Alcohol Together?](https://cedclinic.com/can-you-mix-weed-and-alcohol/) Clinical context on alcohol and cannabinoid co-use, impairment, and safety. [Review co-use safety](https://cedclinic.com/can-you-mix-weed-and-alcohol/)[Marijuana Use Up, Alcohol Use Down](https://cedclinic.com/marijuana-alcohol-substitution-trends/) Population-level context that should not be confused with treatment evidence. [Compare population trends](https://cedclinic.com/marijuana-alcohol-substitution-trends/)[The Biochemical Pathways of THC and CBD](https://cedclinic.com/d63-the-biochemical-pathways-of-thc-and-cbd-png/) A general cannabinoid pharmacology explainer for interpreting mechanism claims. [Explore cannabinoid pharmacology](https://cedclinic.com/d63-the-biochemical-pathways-of-thc-and-cbd-png/) ## Frequently Asked Questions What did the CBD trial test? It tested whether 800 mg daily CBD changed brain, cognitive, anxiety, or craving responses during threat anticipation in adults with alcohol use disorder. Was the study randomized? Yes. It used a randomized, double-blind, placebo-controlled crossover design. How many people contributed data? Sixteen contributed complete behavioral data and fourteen contributed analyzable fMRI data. Did CBD change brain activation? No significant regional or whole-brain CBD effect remained after the planned corrections. Did CBD reduce anxiety or craving? No significant CBD effect was detected on anxiety or craving during the task. Did CBD improve cognitive task performance? No significant CBD effect was detected on task accuracy or response latency. Were serious adverse events reported? No serious adverse events were reported during this brief study. Did the trial show that CBD treats alcohol use disorder? No. It did not test abstinence, relapse, treatment retention, or long-term drinking outcomes. What was the main limitation? The analyzable sample was very small, non-treatment-seeking, and five imaging datasets were excluded for poor quality. Should patients use 800 mg CBD for alcohol problems? This study provides no basis for self-treatment. High-dose CBD requires clinical review for interactions, adverse effects, and appropriate care options. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).